Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 16/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433177 | 0.97 | MPO (0.55) | MPOSLC6A4HTR1A | |
| SCHEMBL28496644 | 0.93 | MPO (0.51) | MPOSLC6A4HTR1A | |
| SCHEMBL9213281 | 0.91 | HTR2A (0.48) | MPOSLC6A4HTR1A | |
| SCHEMBL9215791 | 0.87 | SLC6A4 (0.52) | SLC6A4HTR1A | |
| SCHEMBL16433094 | 0.86 | MAPT (0.57) | SLC6A4HTR1A | |
| SCHEMBL16433322 | 0.84 | SLC6A4 (0.55) | SLC6A4HTR1A | |
| SCHEMBL320187 | 0.84 | NR3C1 (0.52) | SLC6A4HTR1A | |
| SCHEMBL3702253 | 0.83 | MPO (0.62) | MPOSLC6A4 | |
| SCHEMBL16432776 | 0.83 | SLC6A4 (0.51) | SLC6A4HTR1A | |
| SCHEMBL16433285 | 0.83 | MAPT (0.56) | SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112209917-B | Application of heterocyclic substituted phenylpiperazine or phenylpiperidine derivatives in antidepressant drugs | 上海医药工业研究院 | 2021-09-24 | — | — | CN | disclosed |
| CN-112209917-A | Application of heterocyclic substituted phenyl piperazine (pyridine) derivatives in antidepressant drugs | 上海医药工业研究院 | 2021-01-12 | — | — | CN | disclosed |
| EP-3027607-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-9714232-B2 | Substituted piperazine compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-9598401-B2 | Substituted heteroaryl compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-21 | — | — | US | disclosed |
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| EP-3027607-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-06-08 | — | — | EP | disclosed |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-24 | — | — | US | disclosed |
| WO-2015014256-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-02-05 | — | — | WO | disclosed |
| WO-2009137733-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2000040580-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINYL-METHYL[3-(1H-INDOL-3-YL)-ALKYL]-AMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999051575-A1 | N-ARYLOXYETHYL-INDOLY-ALKYLAMINES FOR THE TREATMENT OF DEPRESSION (5-HT1A RECEPTOR ACTIVE AGENTS) | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0464604-B1 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0464558-B1 | Antimigraine alkoxypyrimidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0464604-A2 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464558-A1 | Antimigraine alkoxypyrimidine derivatives | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
| US-5077293-A | Antidepressants | BRISTOL-MYERS SQUIBB CO. (US) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | HTR5A, HTR2A, HTR2C | MPO 1456/4885SLC6A4 19/4885HTR1A 6/4885 |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HTR3B, HTR3A, HTR2C | MPO 3540/4885SLC6A4 19/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.